Development of type 1 diabetes in a patient treated with anti‐interleukin‐6 receptor antibody for rheumatoid arthritis

Interleukin‐6 is a pleiotropic cytokine that plays a pathogenic role in type 1 diabetes. Therefore, anti‐interleukin‐6 receptor antibody, tocilizumab, used for the treatment of rheumatoid arthritis, is considered a candidate for immune intervention in type 1 diabetes. Here, we report the case of a 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawasaki, Eiji, Fukuyama, Takahiro, Uchida, Aira, Sagara, Yoko, Nakano, Yuko, Tamai, Hidekazu, Tojikubo, Masayuki, Hiromatsu, Yuji, Koga, Nobuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017619/
https://www.ncbi.nlm.nih.gov/pubmed/34743422
http://dx.doi.org/10.1111/jdi.13706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017619/
https://www.ncbi.nlm.nih.gov/pubmed/34743422
http://dx.doi.org/10.1111/jdi.13706

Ejemplares similares